Uveitis Development orphan status
November 20, 2014 at 11:48 AM EST
I just read (watched) a presentation from Mike Ward of Wall Street Insights & indictments for a biotech newsletter touting a $4 stock for a $28 million California company that has just received (or is about to) orphan status for a new Uveitis drug. ABBV has one listed, but is a $65 stock. Any one […]
